Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli.
Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.